Tempus AI, Inc. $TEM Shares Sold by Victory Financial Group LLC

Victory Financial Group LLC trimmed its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 45.2% during the third quarter, Holdings Channel reports. The firm owned 15,000 shares of the company’s stock after selling 12,377 shares during the quarter. Victory Financial Group LLC’s holdings in Tempus AI were worth $1,228,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Park Avenue Securities LLC acquired a new stake in shares of Tempus AI in the third quarter valued at $214,000. Maxi Investments CY Ltd purchased a new stake in shares of Tempus AI in the 3rd quarter valued at $2,662,000. Apollon Wealth Management LLC raised its holdings in shares of Tempus AI by 26.8% in the 3rd quarter. Apollon Wealth Management LLC now owns 6,872 shares of the company’s stock valued at $563,000 after buying an additional 1,451 shares during the period. Capelight Capital Asset Management LP acquired a new position in Tempus AI during the 3rd quarter worth about $4,095,000. Finally, Signaturefd LLC lifted its stake in Tempus AI by 102.7% during the 3rd quarter. Signaturefd LLC now owns 1,865 shares of the company’s stock worth $153,000 after acquiring an additional 945 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEM has been the subject of a number of research analyst reports. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Rothschild & Co Redburn assumed coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price target on the stock. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Roth Capital started coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Tempus AI from $45.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 14th. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $72.47.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Large Bristol Myers Squibb and Pathos agreement: Tempus disclosed agreements expected to provide approximately $192.5 million in aggregate cash payments over about five years. The oncology portion gives Bristol Myers Squibb access to Tempus’ multimodal oncology data, Lens software and related analytical services through 2031, strengthening the company’s recurring data and applications revenue outlook. Tempus AI Gains After New Bristol Myers Deal and EU Diagnostic Certification
• Positive Sentiment: European regulatory milestone: Tempus’ xR RNA-sequencing assay received EU IVDR Class C certification for solid-tumor genomic profiling. The certification may support broader adoption of the diagnostic in Europe and enhance the credibility of Tempus’ clinical testing business. Tempus Receives IVDR Certification for xR RNA Sequencing
• Positive Sentiment: Analyst support and earnings expectations: BTIG reaffirmed its buy rating and an $80 price target. Analysts are also expecting Tempus to potentially exceed consensus estimates in the upcoming report, which could provide another catalyst if revenue growth and cash management meet expectations. Tempus AI Expected to Beat Earnings Estimates
• Neutral Sentiment: Personalis acquisition remains an important uncertainty: Tempus has a pending approximately $1.5 billion deal for Personalis. Investors may look to the earnings report for updates on closing, financing and the strategic benefits of the transaction. The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
• Negative Sentiment: Profitability and dilution concerns persist: Tempus remains unprofitable, and continued cash burn could pressure the valuation or require additional financing. In addition, reported insider activity over the past six months consisted entirely of sales, including substantial selling by senior executives, which may weigh on investor sentiment. What Happens To Tempus AI Stock If Its Cash Burn Continues?

Insider Activity

In related news, CEO Ryan Fukushima sold 700 shares of Tempus AI stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the transaction, the chief executive officer owned 15,874 shares in the company, valued at $1,111,180. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan Bartolucci sold 7,062 shares of Tempus AI stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the transaction, the chief accounting officer owned 60,804 shares of the company’s stock, valued at $4,560,300. This represents a 10.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,030,965 shares of company stock valued at $69,882,564. 24.26% of the stock is owned by corporate insiders.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $72.15 on Wednesday. The company has a market cap of $13.02 billion, a price-to-earnings ratio of -50.10 and a beta of 3.54. The stock’s 50-day moving average is $69.70 and its two-hundred day moving average is $56.95. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $92.00.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. Equities research analysts anticipate that Tempus AI, Inc. will post -1.43 earnings per share for the current fiscal year.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.